Isavuconazole for the Treatment of Cerebral Aspergillosis: A Retrospective European EFISG Study

Isavuconazole for the Treatment of Cerebral Aspergillosis: A Retrospective European EFISG Study

Cerebral aspergillosis (CA) is a lethal invasive fungal infection, with current national and international guidelines recommending voriconazole as the first-line antifungal treatment. While newer triazoles, such as isavuconazole, demonstrate good blood-brain barrier penetration, there is still limited clinical evidence to confirm their efficacy and safety for treating CA. Recently, Clinical Infectious Diseases published a retrospective study led by the European Fungal Infection Study Group (EFISG) of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID). The study highlights that isavuconazole is well-tolerated in the treatment of CA, with mortality rates comparable to those of voriconazole.
Dr. Jianxiang Wang: Leading Research, Continuous Innovation! Focusing on the Practice and Vision of CAR-T Cell Therapy in China

Dr. Jianxiang Wang: Leading Research, Continuous Innovation! Focusing on the Practice and Vision of CAR-T Cell Therapy in China

In early September 2024, the 5th Tianjin International Lymphoma Conference was held from September 6 to 8, amid the golden season of autumn. This conference featured 12 specialized sessions, including immunotherapy, basic translational research, and new drug development, creating a high-end academic platform for international exchange and collaboration. During the event, Hematology Frontier invited Dr. Jianxiang Wang from the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College to provide an in-depth analysis of the current state and future trends of CAR-T cell therapy in China from his academic perspective.
Dr. Wei Sang: Analysis of CAR-T Efficacy and Challenges in Various Hematologic Malignancies at the 5th Tianjin International Lymphoma Conference

Dr. Wei Sang: Analysis of CAR-T Efficacy and Challenges in Various Hematologic Malignancies at the 5th Tianjin International Lymphoma Conference

From September 6 to 8, 2024, the 5th Tianjin International Lymphoma Conference was successfully held. The conference featured 12 specialized sessions, including immunotherapy, translational research, and new drug development, creating a platform for international academic exchange and cooperation. During the event, Hematology Frontier invited Dr. Wei Sang from The Affiliated Hospital of Xuzhou Medical University to provide an in-depth analysis of CAR-T cell therapy in different hematologic malignancies and explore strategies for optimizing treatment outcomes.
Expert Insights from the 2024 ESMO Congress l The INSPIRE Study Shines on the International Stage Once Again

Expert Insights from the 2024 ESMO Congress l The INSPIRE Study Shines on the International Stage Once Again

The European Society for Medical Oncology Congress 2024(ESMO 2024) opened on September 13, in Barcelona,Spain. Lung cancer remains one of the key areas of focus,with several groundbreaking studies presented at the conference. Oncology Frontier invited Dr.Yuankai Shi, principal investigator of the INSPIRE study from the Cancer Hospital Chinese Academy of Medical Sciences,to share the latest data from this year's ESMO conference and discuss the clinical value of the study in treating anaplastic lymphoma kinase(ALK)-positive advanced non-small cell lung cancer(NSCLC).
Gut丨MED12 Loss Activates Retrotransposons to Enhance Immunotherapy Sensitivity in Pancreatic Cancer

Gut丨MED12 Loss Activates Retrotransposons to Enhance Immunotherapy Sensitivity in Pancreatic Cancer

Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers, characterized by high mortality rates and limited treatment options. Immunotherapy, particularly immune checkpoint blockade (ICB), has shown remarkable efficacy in treating cancers like melanoma and non-small cell lung cancer. However, many PDAC patients exhibit poor responses to ICB, mainly due to the tumor’s low immunogenicity and its immunosuppressive tumor microenvironment (TME). Inhibiting epigenetic regulators, such as SETDB1, KDM5B, and PHF8, has been shown to induce retrotransposon-mediated immune responses, thereby enhancing sensitivity to immunotherapy. While this approach shows promise in cancer treatment, its role in PDAC remains unclear. A recent study published in Gut identifies the key role of MED12 in modulating TME through the epigenetic silencing of retrotransposons, thus reshaping the immune TME in PDAC.